Concepts (128)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Peptides | 18 | 2024 | 372 | 3.310 |
Why?
|
| Proteins | 6 | 2026 | 382 | 1.930 |
Why?
|
| Histocompatibility Antigens Class I | 7 | 2022 | 32 | 1.370 |
Why?
|
| Software | 2 | 2026 | 236 | 1.310 |
Why?
|
| Molecular Dynamics Simulation | 5 | 2026 | 188 | 1.260 |
Why?
|
| T-Lymphocytes | 4 | 2024 | 386 | 1.110 |
Why?
|
| Receptors, Antigen, T-Cell | 5 | 2024 | 69 | 1.080 |
Why?
|
| Neoplasms | 5 | 2023 | 1377 | 1.060 |
Why?
|
| Models, Molecular | 11 | 2020 | 876 | 0.800 |
Why?
|
| Cross Reactions | 5 | 2019 | 87 | 0.720 |
Why?
|
| CD8-Positive T-Lymphocytes | 6 | 2025 | 184 | 0.690 |
Why?
|
| HIV Protease | 2 | 2026 | 23 | 0.660 |
Why?
|
| Protein Conformation | 7 | 2026 | 416 | 0.640 |
Why?
|
| Major Histocompatibility Complex | 4 | 2024 | 29 | 0.640 |
Why?
|
| Protein Binding | 12 | 2024 | 1082 | 0.630 |
Why?
|
| HLA Antigens | 2 | 2022 | 27 | 0.590 |
Why?
|
| Epitopes | 6 | 2024 | 157 | 0.550 |
Why?
|
| Hepacivirus | 2 | 2015 | 74 | 0.440 |
Why?
|
| Nelfinavir | 1 | 2014 | 4 | 0.420 |
Why?
|
| Databases, Protein | 6 | 2020 | 54 | 0.420 |
Why?
|
| HIV Protease Inhibitors | 1 | 2014 | 24 | 0.420 |
Why?
|
| Drug Design | 1 | 2015 | 186 | 0.420 |
Why?
|
| Drug Resistance, Viral | 1 | 2014 | 67 | 0.410 |
Why?
|
| Binding Sites | 5 | 2020 | 671 | 0.410 |
Why?
|
| Mutation, Missense | 1 | 2014 | 91 | 0.400 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2024 | 38 | 0.400 |
Why?
|
| Algorithms | 5 | 2020 | 509 | 0.380 |
Why?
|
| T-Lymphocytes, Cytotoxic | 3 | 2023 | 32 | 0.350 |
Why?
|
| HLA-A Antigens | 1 | 2011 | 7 | 0.350 |
Why?
|
| Humans | 28 | 2025 | 43102 | 0.350 |
Why?
|
| Immunotherapy | 3 | 2023 | 144 | 0.330 |
Why?
|
| Viral Nonstructural Proteins | 1 | 2011 | 53 | 0.330 |
Why?
|
| Antigen Presentation | 1 | 2010 | 58 | 0.320 |
Why?
|
| Computational Biology | 4 | 2022 | 327 | 0.280 |
Why?
|
| HIV-1 | 1 | 2014 | 755 | 0.270 |
Why?
|
| Ligands | 3 | 2019 | 388 | 0.260 |
Why?
|
| Alleles | 4 | 2024 | 352 | 0.240 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2025 | 17 | 0.240 |
Why?
|
| Drug Discovery | 2 | 2018 | 108 | 0.240 |
Why?
|
| Ubiquitin | 1 | 2026 | 81 | 0.230 |
Why?
|
| Structure-Activity Relationship | 4 | 2020 | 506 | 0.230 |
Why?
|
| Antigens, Neoplasm | 1 | 2025 | 90 | 0.220 |
Why?
|
| Vimentin | 1 | 2024 | 44 | 0.220 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2024 | 58 | 0.210 |
Why?
|
| Hominidae | 1 | 2024 | 12 | 0.210 |
Why?
|
| Amino Acid Sequence | 5 | 2023 | 1180 | 0.200 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2023 | 8 | 0.200 |
Why?
|
| Sulfonamides | 1 | 2024 | 91 | 0.200 |
Why?
|
| Interferon-gamma | 1 | 2024 | 269 | 0.190 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2022 | 31 | 0.190 |
Why?
|
| Hepatitis C | 2 | 2015 | 139 | 0.180 |
Why?
|
| Computer Simulation | 3 | 2020 | 408 | 0.170 |
Why?
|
| Markov Chains | 1 | 2020 | 43 | 0.170 |
Why?
|
| Complement C3 | 1 | 2020 | 16 | 0.160 |
Why?
|
| Peptides, Cyclic | 1 | 2020 | 29 | 0.160 |
Why?
|
| Lung Neoplasms | 1 | 2025 | 495 | 0.160 |
Why?
|
| Hepatitis E | 1 | 2019 | 3 | 0.160 |
Why?
|
| Hepatitis E virus | 1 | 2019 | 3 | 0.160 |
Why?
|
| DNA-Binding Proteins | 1 | 2023 | 561 | 0.150 |
Why?
|
| Deuterium Exchange Measurement | 1 | 2018 | 2 | 0.150 |
Why?
|
| Complement C3b | 1 | 2018 | 4 | 0.150 |
Why?
|
| Multiprotein Complexes | 1 | 2019 | 56 | 0.140 |
Why?
|
| Interleukin-8 | 1 | 2018 | 74 | 0.140 |
Why?
|
| Antiviral Agents | 1 | 2020 | 195 | 0.140 |
Why?
|
| Cell Membrane | 1 | 2020 | 403 | 0.140 |
Why?
|
| Conserved Sequence | 2 | 2015 | 122 | 0.120 |
Why?
|
| Static Electricity | 2 | 2015 | 86 | 0.110 |
Why?
|
| Viral Vaccines | 1 | 2015 | 37 | 0.110 |
Why?
|
| Iduronidase | 1 | 2014 | 1 | 0.110 |
Why?
|
| Internet | 1 | 2015 | 236 | 0.100 |
Why?
|
| Amino Acid Substitution | 1 | 2014 | 135 | 0.100 |
Why?
|
| Viral Core Proteins | 1 | 2012 | 12 | 0.090 |
Why?
|
| Acquired Immunodeficiency Syndrome | 1 | 2014 | 226 | 0.090 |
Why?
|
| Protein Isoforms | 2 | 2023 | 139 | 0.090 |
Why?
|
| Nucleoside-Triphosphatase | 1 | 2011 | 13 | 0.090 |
Why?
|
| Capsid Proteins | 1 | 2012 | 76 | 0.090 |
Why?
|
| Crystallography, X-Ray | 3 | 2019 | 280 | 0.090 |
Why?
|
| DEAD-box RNA Helicases | 1 | 2011 | 25 | 0.090 |
Why?
|
| Serine Endopeptidases | 1 | 2011 | 48 | 0.080 |
Why?
|
| Principal Component Analysis | 1 | 2011 | 87 | 0.080 |
Why?
|
| Immunity, Cellular | 1 | 2011 | 74 | 0.080 |
Why?
|
| Molecular Conformation | 1 | 2010 | 155 | 0.080 |
Why?
|
| Citrulline | 1 | 2024 | 14 | 0.060 |
Why?
|
| Animals | 4 | 2025 | 16992 | 0.050 |
Why?
|
| Lymphocyte Activation | 1 | 2025 | 249 | 0.050 |
Why?
|
| Clone Cells | 1 | 2023 | 50 | 0.050 |
Why?
|
| Genes, MHC Class I | 1 | 2023 | 15 | 0.050 |
Why?
|
| Mutation | 2 | 2020 | 1177 | 0.050 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2024 | 185 | 0.050 |
Why?
|
| Mammals | 1 | 2023 | 112 | 0.050 |
Why?
|
| Systems Biology | 1 | 2022 | 27 | 0.050 |
Why?
|
| Epitopes, T-Lymphocyte | 1 | 2022 | 60 | 0.050 |
Why?
|
| Placenta | 1 | 2023 | 117 | 0.050 |
Why?
|
| Reproducibility of Results | 2 | 2015 | 1081 | 0.040 |
Why?
|
| Prognosis | 1 | 2024 | 861 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2024 | 734 | 0.040 |
Why?
|
| Alanine | 1 | 2020 | 34 | 0.040 |
Why?
|
| Binding, Competitive | 1 | 2020 | 109 | 0.040 |
Why?
|
| Protein Interaction Domains and Motifs | 1 | 2020 | 41 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2020 | 95 | 0.040 |
Why?
|
| Proline | 1 | 2020 | 40 | 0.040 |
Why?
|
| Protein Stability | 1 | 2020 | 48 | 0.040 |
Why?
|
| Hydrogen Bonding | 1 | 2020 | 144 | 0.040 |
Why?
|
| Lipid Bilayers | 1 | 2020 | 57 | 0.040 |
Why?
|
| HLA-A2 Antigen | 1 | 2019 | 4 | 0.040 |
Why?
|
| Protein Multimerization | 1 | 2020 | 115 | 0.040 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2019 | 26 | 0.040 |
Why?
|
| Amino Acid Motifs | 1 | 2019 | 97 | 0.040 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 83 | 0.040 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 88 | 0.040 |
Why?
|
| Transcription Factors | 1 | 2023 | 735 | 0.030 |
Why?
|
| Phylogeny | 1 | 2022 | 769 | 0.030 |
Why?
|
| Pregnancy | 1 | 2023 | 1772 | 0.030 |
Why?
|
| Serotyping | 1 | 2015 | 37 | 0.030 |
Why?
|
| Hepatitis C Antibodies | 1 | 2015 | 10 | 0.030 |
Why?
|
| Dengue Vaccines | 1 | 2015 | 16 | 0.030 |
Why?
|
| Mucopolysaccharidosis I | 1 | 2014 | 1 | 0.030 |
Why?
|
| Cluster Analysis | 1 | 2015 | 207 | 0.030 |
Why?
|
| Dengue Virus | 1 | 2015 | 96 | 0.030 |
Why?
|
| Protein Structure, Secondary | 1 | 2014 | 182 | 0.030 |
Why?
|
| Software Design | 1 | 2013 | 18 | 0.020 |
Why?
|
| Information Storage and Retrieval | 1 | 2013 | 35 | 0.020 |
Why?
|
| User-Computer Interface | 1 | 2013 | 74 | 0.020 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 2012 | 267 | 0.020 |
Why?
|
| Multivariate Analysis | 1 | 2013 | 638 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2015 | 1759 | 0.020 |
Why?
|
| Female | 1 | 2023 | 24698 | 0.010 |
Why?
|
| Mice | 1 | 2013 | 6644 | 0.010 |
Why?
|